Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic colorectal cancer: Princeton, New Jersey Monday, November 18, 2 ...
GlobalData on MSN15h
EMA’s CHMP to approve BMS’ Opdivo for colorectal cancerThe EMA's CHMP has recommended approval of a combination therapy of BMS's Opdivo and Yervoy for the treatment of colorectal ...
EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...
The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.
Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
Hello, Reader. For all that artificial intelligence has accomplished over the last few years, one thing it has not yet ...
On September 16, 2024, Immatics announced the proof-of-concept clinical data for the first candidate of its next-generation, ...
An Investigational New Drug application for the Nectin4/TROP2 ADC is planned for submission to the U.S. Food and Drug Administration in ... played an integral role in its acquisition by Bristol Myers ...
We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
Detailed price information for Medicus Pharma Ltd (MDCX-X) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback